Podcasts about scientific affairs

Matthew "Oki" O'Connor is the CEO of Scientific Affairs at Cyclarity Therapeutics, a clinical-stage biotech building a new class of medicines designed not to slow the accumulation of vascular damage but to reverse it. Oki and Chris first crossed paths as postdocs at Lawrence Berkeley National Lab in the mid-2000s — Oki was in Irina Conboy's lab, not far from the late Judy Campisi's group, where Chris was then working on cellular senescence. After Berkeley, Oki spent nearly a decade running the research program at the SENS Research Foundation, the organization most identified with the "damage repair" framing of aging biology, before co-founding Cyclarity (then known as Underdog Pharmaceuticals) in 2019 to translate one of SENS's most drug-tractable ideas into an actual molecule.When Oki was last on the show in March of 2023 (Episode 36), Cyclarity was deep in IND-enabling work and its lead asset, UDP-003, had only ever seen the inside of a mouse artery. At the end of that conversation, Chris asked what Oki hoped to be discussing the next time he visited. He answered, bluntly, that he wanted to be presenting human data. Last month, at the AHA Vascular Discovery Sessions, Cyclarity reported the results of their first-in-human Phase 1 trial of UDP-003 — a designed cyclodextrin that selectively binds 7-ketocholesterol, the oxidized cholesterol species that drives foam cell formation and arterial plaque. He's back to discuss what the drug actually did when it went hunting for 7KC inside a living human being.In this episode, Chris and Oki cover the unmet need that lipid-lowering drugs — statins, PCSK9 inhibitors, the coming Lp(a) agents — still don't address: none of them remove the damage already sitting in an artery wall. Oki explains the basic chemistry of 7-ketocholesterol and why macrophages, lacking the machinery to recycle it, collapse into foam cells and seed the necrotic core of advanced plaque. They walk through the engineering of UDP-003 as a dimeric beta-cyclodextrin "double cone" tuned for a single oxidized cholesterol species, the design of the 72-volunteer Australian Phase 1, and the exploratory pharmacodynamic readout that has the field's attention: dose-dependent urinary excretion of 7KC, stoichiometric with drug, cleared within a day. The conversation then turns to the 150-patient Phase 2 plan in coronary artery disease patients with plaque imaging as the primary biological readout, the funding math that stands between Cyclarity and that trial, the platform's reach into NASH, vascular dementia, AMD, and aging itself, and how all of this descends from the SENS damage-repair philosophy that Oki has been carrying since LBL.The Finer Details:- Why current standard of care is not enough — statins, PCSK9 inhibitors, GLP-1s, and the soon-to-arrive Lp(a) lowering agents all act by slowing the accumulation of arterial damage, not by reversing what's already there; despite 30 years on the market, statins have never demonstrated an all-cause mortality benefit in a clinical trial, and even the best statin imaging data shows only 1–2% plaque volume regression at very high doses in a subset of patients- The scale of the problem — atherosclerosis is estimated to contribute to roughly 40% of all human deaths once heart attack, stroke, and a surprisingly large COPD contribution are risk-adjusted in, on top of an enormous morbidity tail that includes angina, peripheral artery disease (up to and including amputation), and a growing case for vascular dementia as an undercounted driver of cognitive decline- The biology of 7-ketocholesterol — when an oxygen free radical reacts with cholesterol, it preferentially attacks the 7 position, and a second oxidation step locks the molecule into 7KC, a stable toxic species cells were essentially never equipped to recycle; it builds up in long-lived cells like macrophages, eventually shutting down their ability to traffic lipids back to the liver via HDL and converting them into foam cells that seed soft plaque and, over years, the necrotic core of advanced lesions- The molecular design of UDP-003 — cyclodextrins are naturally occurring carbohydrate rings; the beta size fits half a cholesterol molecule, and Cyclarity's in silico work showed that two beta-cyclodextrins facing wide-side to wide-side form a "double cone" that can fully encapsulate a single cholesterol; engineered correctly, that wrapper can be made selective for 7KC over native membrane cholesterol, which is what gives the drug its therapeutic window- The Phase 1 trial design and result — a traditional 72-volunteer safety study in Australia, split between single ascending dose and multiple ascending dose arms, escalating up to six doses at what Cyclarity believes will be the efficacious level; no serious adverse events, no bioaccumulation, drug excreted essentially completely in the urine (as predicted preclinically), and — the headline exploratory endpoint — dose-dependent urinary 7-ketocholesterol appearing on the same timescale as the drug, consistent with one molecule of UDP-003 binding one molecule of 7KC and leaving the body together- What the urinary 7KC readout can and cannot tell you — the easiest 7KC to mobilize is the free pool in circulation, but there is not nearly enough of it floating in the bloodstream to account for what came out in urine, which means the drug is reaching deeper compartments; how much is coming from vessel wall plaque versus liver versus other peripheral tissues will require the imaging endpoints of Phase 2 to answer- The Phase 2 plan — 150 coronary artery disease patients (the coronary being, as Oki puts it, the artery most likely to kill you), with baseline plaque imaging, a year of dosing, and a repeat scan; safety and PK continue, inflammatory biomarkers come on, and plaque volume change is the prize — for context, a 1% change in plaque volume is associated with roughly a 20% change in next-year risk of heart attack or stroke- The funding math and the platform — Cyclarity has raised $33M to date and needs roughly $45M more to run the Phase 2, with Phase 3 cardiovascular outcomes trials running into the hundreds of millions and likely requiring a pharma partner; beyond atherosclerosis, 7KC is elevated in NASH livers, in Alzheimer's brains, and in the retinal cells that die in age-related macular degeneration, and the underlying chemistry — designed binders that drag a specific toxic molecule out of the body — is meant to generalize into a pipeline against other accumulated damage species, the direct intellectual descendant of the SENS damage-repair programQuotes:"Atherosclerosis, or the plaque that builds up in your blood vessels in your arteries, is estimated to cause approximately 40% of all human death.""When [the macrophage] eats up too much oxidized cholesterol, it just accumulates it… And that's when you get this transition to these kind of monster blob cells called foam cells.""One molecule of our drug is supposed to bind one molecule of 7-ketocholesterol and then go away and never be seen again. You excrete both of them together.""A 1% change in plaque volume is associated with a 20% risk in the next year of your probability of having a heart attack or a stroke.""You pick one target at a time, you do it well, and you take it all the way to the clinic and hopefully prove that you can actually cure patients, help them get better, help their plaque shrink away, and prove that this approach can work."Links:Cyclarity Therapeutics: https://cyclarity.com

Elevated GP - Click here to join Elevated.GP Follow @dr.melissa_seibert on Instagram Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

NAD is the molecule in every cell that powers your energy — and there's a kind of exhaustion, the kind a good night's sleep and a weekend off can't fix, that comes from running low on it. If you're a woman in your 40s, 50s, or 60s caring for aging parents while raising kids and running a career — the sandwich generation — that depletion is real, and it's happening at the cellular level. In this episode, Dr. Caroline Leaf sits down with Mona Rosene, MS, RD, Global Director of Scientific Affairs at Niagen Bioscience, to explore NAD — the coenzyme that powers your mitochondria and fuels over 500 metabolic processes. NAD drops roughly 65% between the ages of 30 and 70, and chronic stress, menopause, poor sleep, and illness deplete it even faster. Mona explains what that means for your energy, brain fog, hormones, and inflammation — and what you can actually do about it.

To get a taste of the discussions that were happening at the 2026 Food Safety Summit, we spoke face-to-face with Roberta Wagner, M.Sc., Senior Vice President of Regulatory and Scientific Affairs for the International Dairy Foods Association (IDFA); Steven Mandernach, J.D., Executive Director of the Association of Food and Drug Officials (AFDO) and Sandra Eskin, J.D., CEO of STOP Foodborne Illness; Jacob Nelson, Asset Protection Sales Manager at the Sherwin-Williams Company and Feraas Aiameh, Food and Beverage Marketing Manager at the Sherwin-Williams Company; Conrad Choiniere, Ph.D., Director of  the U.S. Food and Drug Administration's (FDA's) Office of Microbiological Food Safety, Vanessa Coffman, Ph.D., Director of the Alliance to Stop Foodborne Illness, and Lone Jespersen, Ph.D., Founder and Principal of Cultivate SA; and Cindy Jiang, Senior Director, Global Food Safety Risk Management, Global Supply Chain at McDonald's (retired). In this episode of Food Safety Matters, we speak with: Ms. Wagner about food ingredient safety and labeling trends, policy developments, and risk communication [2:48] Mr. Mandernach and Ms. Eskin about progress and gaps in the implementation of FDA's Food Safety Modernization Act (FSMA) in the 15 years since it was passed [26:19] Mr. Nelson and Mr. Aiameh about a facility lifecycle approach to food safety [47:37] Drs. Choiniere, Coffman, and Jespersen about perspectives, challenges, and opportunities related food safety culture across sectors [1:16:42] Ms. Jiang about practical applications for artificial intelligence (AI) in food safety. [1:44:37] Sponsored by: Sherwin Williams We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

Halle Raicevich, Research Associates Manager; Rick Renko, Project Manager, Regulatory & Scientific Affairs; and Alexa Kehoe, Senior Clinical Project Coordinator, are featured on this episode of the Moving Medicine Forward podcast to discuss CTI's Research Associate (RA) Program. This pathway is designed to help emerging talent gain real‑world experience while exploring opportunities across the industry. Tune in to explore the value of mentorship and early exposure for professionals beginning their careers and learn how CTI's people‑first culture supports growth at every stage.00:51 Meet the guests: Halle Raicevich, Ricky Renko, and Alexa Kehoe01:23 Overview of the RA program and its role as an entry point into clinical research03:00 Why CTI invests in early‑career development and hands‑on learning04:08 How cross‑department exposure builds confidence and strengthens collaboration04:49 A typical day for a Research Associate05:57 Skills gained through the RA role07:06 The importance of flexibility and mentorship08:20 How the RA program supports long‑term career growth across functions09:18 Expanding the RA program internationally and lessons learned from global implementation10:56 Developing future leaders through mentorship12:23 Advice for those considering the RA program or a career in clinical research14:27 Community involvement and CTI's people‑first culture16:37 Why the program is a powerful career foundation

Janine Barr, a researcher at the Bloustein School's Environmental Analysis and Communication (EAC) Group, joins Dean Stuart Shapiro this week on EJB Talks to discuss the center's work on climate change impacts. A self-proclaimed Jersey girl, Janine traces her path to environmental policy back to an internship with the U.S. Department of State's Bureau of Oceans and International Environmental and Scientific Affairs. The internship not only drew her toward environmental policy, but specifically toward issues affecting her home state. She describes how the EAC Group brings together the branches of policy, planning, and public health to integrate community needs into local, regional, and state planning initiatives, supported by robust stakeholder engagement and data analysis. Janine also speaks to her involvement with the New Jersey Sea Level Rise and Coastal Storms Science and Technology Advisory Panel (STAP) Report, a major effort to equip decision-makers with updated science on sea level rise and coastal storms. The report projects sea level rise of 1.8 to 4.3 feet by 2100 depending on emissions scenarios. She closes by stressing the importance of clear, ongoing communication with the public, so communities can meaningfully engage with questions of risk tolerance and long-term planning needs.Links mentioned in today's podcast:New Jersey Climate Change Resource Centers Science and Technology Advisory Panel (STAP) Report websiteSTAP Report Summary and FAQ document (PDF, short)Full STAP Report (PDF)NJ REAL Rules

Could psychedelics open new doors in medicine, or are patients being asked to trust the promise before the proof is in?Sign up for weekly webinars: Weekly Webinars - Independent Medical Alliance This episode of IMA's Weekly Show aired Wednesday, April 29, 2026.Dr. Ryan Cole, IMA Head of Medical & Scientific Affairs, sits down with Dr. Molly Rutherford, IMA Senior Fellow in Family Medicine and Addiction Medicine, to separate hope from hype around psychedelic-assisted therapies.They discuss:• Why interest in psychedelic-assisted therapies is growing now• What the current science does and does not show• Why these substances have been difficult to study• The risks of moving too quickly toward unproven treatments• What responsible progress could look like for patients, families, and physiciansThe bottom line: when a treatment changes lives, it deserves to be studied carefully, not rushed blindly.First aired 29th April 2026Also:• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

Nothing in biology is random. Not growth. Not metabolism. Not disease. What we will explore today is the reality that the earliest inputs in life: nutrition, environment, signaling, don't just influence outcomes… They shape them. They write the first draft. And if you understand that, if you truly let that land, then everything about how we approach pregnancy, childhood, and prevention begins to shift. From reaction…to intention. From downstream management…to upstream design. Why This Conversation Matters This episode is not just another discussion. In many ways, it is ground zero. Because if you don't understand this layer, the imprinting, the epigenetic programming, the responsiveness of biology to environment, then everything that follows in this podcast…becomes harder to fully see. But once you do see it, the picture sharpens. You begin to understand:why trajectories diverge early, why children present so differently and why the same diagnosis can have completely different roots. This is the beginning of a new map. And maps matter. Gratitude to Today's Guests I want to take a moment to acknowledge the voices you heard today—because this kind of thinking doesn't happen by accident. Lucia Aronica Dr. Aronica is a Stanford scientist and a global authority in nutritional epigenetics, helping clinicians understand that food is not simply fuel—it is biological information that actively programs gene expression. She created Stanford's first courses in nutritional epigenetics and pioneered the Epinutrition framework, a clinical model that reframes nutrition as signaling, not supplementation. You may recognize her from the Netflix documentary You Are What You Eat: A Twin Experiment, and she is now launching the world's first Clinical Epinutrition Certification, training health professionals to use food as epigenetic medicine. Emily Stone Rydbom Emily is a clinical nutritionist, researcher, and digital health founder working at the frontier of precision maternal nutrition. As Founder and CEO of GrowBaby Health, and through her work with GrowHealth Technologies, she is building AI-enabled systems that integrate nutrition directly into standard obstetric care. With over 14 years of clinical experience, she has helped pioneer the “Standard of Care PLUS” model, demonstrating meaningful reductions in preterm birth and gestational diabetes in high-risk populations. She is also a co-investigator on the ROOT Study—bringing this work directly into real-world maternal care here in North Carolina. Samantha N. Fessler Dr. Fessler brings a deep scientific lens to the intersection of metabolism, inflammation, and perinatal nutrition. With a PhD in Exercise and Nutritional Sciences from Arizona State University, her work has focused on how nutritional strategies can modulate the interplay between immune signaling and metabolic function to improve outcomes for mothers and children. As Director of Scientific Affairs at Needed, she helps translate rigorous science into actionable, evidence-based approaches that clinicians and families can actually use. Randy L. Jirtle And finally, Dr. Randy Jirtle—joining us again—whose work, quite simply, changed how we understand biology. A pioneer in epigenetics and genomic imprinting, Dr. Jirtle's research on the agouti mouse model demonstrated for the first time that environmental inputs—particularly nutrition and chemical exposure—could directly alter gene expression across generations. His work reframed the gene from a fixed sentence…to a responsive system. In fact, Time Magazine once described it this way:“A gene represents less of an inexorable sentence and more of an access point for the environment to modify the genome.” He is a Professor of Epigenetics at North Carolina State University and Senior Scientist at University of Wisconsin–Madison and remains, at his core, a deeply curious thinker. And that curiosity… is what moved this field forward. Final Thought: If there is one takeaway from today, it is this: The environment is not acting on the child. The child is responding to the environment. And that response…is being written into biology. Dr. M

Our latest episode of QuidelOrtho Science Bytes addresses a public health paradox: while early-stage syphilis cases in the U.S. are declining, congenital syphilis continues to rise despite being entirely preventable. Host Josh Casey is joined by Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, to unpack CDC data and explain why missed or delayed screening during pregnancy is driving congenital infections. Together, they explore how syphilis testing works, when infections are being missed and why repeat screening is essential, especially later in pregnancy.   About Our Speaker:  Andrea Ott-Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho Andrea holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and an MBA from New York University. Most recently, she earned a Master of Public Health from Imperial College London. With over 20 years of experience in the medical device industry, Andrea has worked in many different roles, including product development and clinical marketing. In her current role at QuidelOrtho, she manages a team responsible for the development of educational content, scientific publications and evidence generation. Andrea is passionate about increasing awareness of the clinical value of laboratory tests and their impact on improving patient outcomes.

How do we care for patients who once believed changing their gender was the answer, only to find themselves in need of medical care, support, and acknowledgment?This week, IMA Head of Medical and Scientific Affairs and host Dr. Ryan Cole was joined by IMA Senior Fellow in Pediatrics Dr. Katherine Welch, pediatric critical care nurse and founder of The Center for Bioethics and Culture Network Jennifer Lahl, RN, and detransitioner Forrest Smith for an important conversation on the often untold medical, psychological, and legal realities of detransitioning.Together, they examined the gaps in care, recognition, and follow-up that many detransitioners now face, and considered what a more honest, compassionate, and patient-centered response should look like.• Discussion points included:• Why detransitioners are so often overlooked or dismissed• The ongoing medical, psychological, and legal challenges they may face• Where meaningful support, better care, and real progress are beginning to emergeAired Wednesday, April 03, 2026.Also:• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

How has one of the world's darkest industries remained hidden in plain sight?What does that silence say about the institutions that failed to stop it?On this episode of Honest Medicine, Dr. Ryan Cole, IMA Head of Medical & Scientific Affairs, spoke with Jan Jekielek, author and Senior Editor with The Epoch Times, about his book, Killed to Order.Together, they examined the evidence surrounding China's state-directed organ harvesting system and the broader questions it raises about medical ethics, government power, and global silence.In this episode, they discussed:• what Killed to Order reveals about forced organ harvesting in China• how this system operated for years with too little public scrutiny• what these abuses reveal about corruption, censorship, and human rights• why the medical community and the public cannot afford to look awayAired Wednesday, March 25, 2026.Also:• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

What happens when a cancer treatment stops working the way it once did? As tumors adapt and resistance develops, treatment strategy can become a critical part of improving outcomes.Sign up for weekly webinars: Weekly Webinars - Independent Medical Alliance In this episode, Dr. Ryan Cole, IMA Head of Medical & Scientific Affairs, speaks with Dr. Paul Marik, IMA Chief Scientific Officer, about the role of drug cycling in cancer care and why it may be essential for patients facing complex treatment decisions.They cover:• What drug cycling is and how it is used in cancer care• Why changing therapies over time may matter• How tumor adaptation and resistance affect treatment response• What timing, sequencing, and strategy can mean in practiceDr. Marik's new cancer guides and how they may help support patients and familiesThis conversation offers a practical look at why cancer treatment should not always remain fixed and how thoughtful changes in therapy may help shape better outcomes.Aired Wednesday, March 18, 2026.Also:• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

DMI's Kuda Lamin-Bangura, Senior Vice President of Scientific Affairs, and Katie Bambacht, Vice President of Nutrition Affairs at the National Dairy Council, chat with DMI's Scott Wallin about what the 2025–2030 Dietary Guidelines for Americans, which strongly affirm dairy's role as an essential part of a healthy diet, recognizing milk, cheese, and yogurt at all fat levels—including whole milk—as beneficial. Kuda and Katie also talk about the impact of the signing of the "Whole Milk for Healthy Kids" act after being signed into law by President Trump, and what effect it could have on school lunch programs. To learn more about the national dairy checkoff and your local dairy checkoffs, please visit dairycheckoff.com. Host & Guest: Host: Scott Wallin, Vice President of Farmer Communications & Media Relations, Dairy Management Inc. Guest: Kuda Lamin-Bangura, Senior Vice President of Scientific Affairs, National Dairy Council Guest: Katie Bambacht, Vice President of Nutrition Affairs, National Dairy Council

Dr. Susan Wynn earned her DVM from the University of Georgia in 1987. After graduation, she completed a Small Animal Internship and worked in small animal practice for a few years before doing Post-Doctoral work in Immunology and Molecular Pathogenesis. Afterwards. she went back into private practice. She completed a clinical residency in Small Animal Nutrition and was Board Certified in Veterinary Nutrition in 2016. She is currently the Senior Director of Scientific Affairs for Instinct Pet Food.Dr. Wynn has authored three textbooks on integrative medicine, published numerous scientific papers, has lectured extensively on holistic medicine and nutrition, and has been very active in organized veterinary medicine, including founding the Veterinary Botanical Medical Association and serving as President of both the AHVMA and the AAVA. She has been a leader and an inspiration in integrative veterinary medicine for decades.Please enjoy this conversation with Dr. Susan Wynn as we discuss her education, work history, and how Instinct Pet Food supports research, veterinary outreach, and has outstanding sourcing and processing practices.

Ramona is a neuroscientist and scientific strategist with deep experience at the intersection of neuroscience, rehabilitation, and emerging health technologies. She earned her BS in Psychology from Brown University, her PhD in Neuroscience from the Uniformed Services University (where her research focused on the modulation of inflammation following Neurotrauma, including publications on the impact of photobiomodulation on microglial activation), and she completed a postdoctoral fellowship in the Neurology Department at the University of Texas at Austin Dell Medical School.Ramona is the Senior Director of US Medical Affairs for Winback America, and serves as a Scientific Advisor for two start ups, Neuronic and the Brainnovation Network. She specializes in translating complex science into real-world clinical and commercial outcomes — from leading research and publication efforts to building clinician training programs. In these roles, she oversees clinical research, education, and regulatory positioning. At Neuronic specifically, she supports research efforts to demonstrate the efficacy of transcranial photobiomodulation on cognitive function and a variety of neurological conditions.She is passionate about leveraging technology to help people achieve their highest quality of life and brings a practical, collaborative approach to connecting science, clinical practice, and business strategy. SHOWNOTES:

This episode is sponsored by Timeline and AquaTru. Timeline - Support your cells and how you age with Mitopure® Gummies from Timeline. Visit https://timeline.com/FLIPPING50SHOW and save up to 39% off your Mitopure® Gummies. AquaTru - Go to https://AquaTru.com/  now for 20% off (your purifier) using promo code FLIPPING50. AquaTru even comes with a 30-day best-tasting water guarantee.  Other Episodes You Might Like: Previous Episode - Recovery Capacity in Menopause: 4 Studies Revealing Why Rest Isn't Enough Next Episode - Cortisol and Cardio for Women Over 40: What Your Heart Needs Now More Like This: Hormone Balance: Balance SIX Hormones in SEVEN Days Natural Solutions You'll Love for Hormone Balance Resources: Don't know where to start? Book your Discovery Call with Debra. Leave this session with insight into exactly what to do right now to make small changes, smart decisions about your exercise time and energy. Use Flipping 50 Scorecard & Guide to measure what matters with an easy at-home self-assessment test you can do in minutes. Your hormones are quietly changing your gut and it may be influencing far more than bloating or digestion. Estrogen, progesterone, and life stages reshape your microbiome and impact your brain, metabolism, immune system, and longevity.  Let's unpack why fiber diversity, stress management, and exercise are powerful levers for supporting beneficial bacteria and producing short-chain fatty acids that protect long-term health.  Your hormones are quietly changing your gut, and understanding how to work with those changes could be one of the most important longevity strategies you adopt. My Guest: Alicia Galvin is a registered dietitian, integrative and functional nutrition practitioner, and Head of Scientific Affairs at Microbiome Labs. She has practiced as a clinician for over 15 years in her private practice, focusing on GI health, women's health, and immune health. She has also co-founded an online training platform for health practitioners, in an effort to educate on the principles of GI health, from an integrative and functional lens and has mentored hundreds of practitioners. Questions We Answer in This Episode: [00:07:40] What is the microbiome? [00:15:11] What are factors that influence the microbiome, both positively and negatively? [00:22:29] How does the microbiome change over time for a woman? [00:30:35] What is the vaginal microbiome? [00:33:14] How does that change and influence women's health? If this episode made you flip how you see menopause — share it!

Today we're taking a closer look at dental implants and the key factors that influence their long-term success—from what patients can do to lower their risk of peri-implantitis, to whether CBCT imaging has become the new standard of care in implant dentistry. We'll also examine the role of systemic health, including the connection between bisphosphonate use and osteonecrosis of the jaw, as well as the latest insights on how antacids, particularly proton pump inhibitors, may affect implant outcomes. Our guest is Dr. Jon Suzuki, Professor of Microbiology and Immunology and of Periodontology and Oral Implantology at Temple University. A former Dean at the University of Pittsburgh, he has chaired the FDA Dental Products Panel, led the ADA Council on Scientific Affairs, and served on numerous NIH committees. A Diplomate of the American Board of Periodontology, he has published over 200 papers and a textbook, and continues to educate dentists all over the world. Thanks to our episode sponsors: EMS Dental - https://www.ems-dental.com/en-us Shofu Dental - https://www.shofu.com/en

Dan Pannier, Propane Operations Manager at Growmark, joins the show to discuss propane supply.Dr. Mandy Carr, Director of Scientific Affairs at the National Cattlemans' Beef Association, describes the scientific side of beef, including safety, nutrition and cattle health.Matt Webster, River Valley Co-Op, joins the program to talk markets.

Stem cells hold promise for understanding human disease, screening for novel therapeutics, and regenerating damaged tissues. However, the mechanisms underlying how these cells form and are activated are still being uncovered, and the development of stem cell-derived tissues for drug screening and transplantation is a work in progress. This conversation with leaders in the field explores the fundamentals of stem cell biology, current stem cell-based therapies, and the ethical considerations shaping the future of stem cell research and its clinical applications. Panel Members Lorenz Studer, Director, Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center Sarah E. Millar, Dean for Academic and Scientific Affairs and Chair of the new Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai In conversation with Kirsten Sadler Edepli, Professor of Biology, NYUAD; Global Network Professor of Biology, NYU

Send us a textDr. Horowitz got to the bottom of the most pressing dental takeaways with Dr. Brian Novy at this year's Chicago Midwinter Meeting. Tune in for a rundown on everything you need to know about everything from disease management, and (drumroll) Dr. Novy's true thoughts on water fluoridization

Welcome back to the Flex Diet Podcast! Today, I'm hanging out with the brilliant Katie Emerson, Senior Manager of Scientific Affairs over at Kyowa Hakko USA, aka the people behind Cognizin (CDP Choline), one of the few brain-boosting ingredients with legit research behind it.We dig into the real science of CDP Choline, how it supports memory, focus, and cognitive performance, and where it actually fits into the human physiology engine, not the hype machine. Katie and I also zoom out into the supplement industry as a whole, chatting about what's worth paying attention to, what's still emerging, and how to navigate all the shiny promises out there.We even take a nerd-tour into mental resilience, genetic mapping, and the surprising potential of glutathione for health and performance.If you're curious how targeted supplements can help you think faster, recover better, and be a more high-performing human without needing a PhD to decode marketing nonsense, this episode is for you.Sponsors:Flex 4: Katie's top 4 things to know about citocholineEpisode Chapters:03:52 Katie Emerson Joins the Conversation04:09 Conversations at ISSN and Networking11:20 Research and Studies on CDP Choline17:49 Challenges in Supplement Formulation24:40 Mechanisms and Benefits of CDP Choline28:06 Exploring Genetic Mapping and Data Overload29:01 Study Design and Dosing Strategies30:29 The Sweet Spot of CDP Choline Dosage33:40 Pharmacokinetics and Timing of CDP Choline35:36 Safety and Side Effects of High Doses38:59 Comparing CDP Choline and Alpha GPC42:41 Introduction to Glutathione48:41 Oral Absorption of Glutathione52:12 Podcast Conclusion and Listener Information Episodes You Might Enjoy:Episode 343: Fueling the Corporate Athlete: Stress, Supplements & Performance with Dan Hunter YouTube: https://youtu.be/0ek4XSs62RQ Episode 222: Expert Insights on nutrition, supplements, and training with Registered Dietitian Sean CaseyYouTube: https://youtu.be/wjJB-y1kwgMConnect with Katie:Cognizin: cognizin.comGet In Touch:Instagram: https://www.instagram.com/drmiketnelson/YouTube: https://www.youtube.com/channel/UCn1aTbQqHglfNrENPm0GTpgEmail: https://miketnelson.com/contact-us/

In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider

Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher's ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

While the cell and gene therapy space represents one of the most exciting therapeutic frontiers in modern biopharma by offering highly personalized, transformative treatments, the sector still faces significant hurdles before it can achieve widespread commercialization. From steep manufacturing costs and a lack of standardization to persistent inefficiencies in scaling production, the road to maturity remains complex. In this episode of Off Script: A Pharma Manufacturing Podcast, we spoke with Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine, about what's driving progress in CGT manufacturing and where the industry is still lagging.

What exactly is a “raw diet,” and how do you make it safely? Host Dr. Alice Jeromin welcomes Dr. Susan Wynn, DVM, DACVIM (Nutrition)—Senior Director of Scientific Affairs at Nature's Variety/Instinct and former president of the American Holistic Veterinary Medical Association—along with JC Cash, CVT. They break down homemade vs. commercial raw diets, high-pressure pasteurization (HPP), supplier quality, SQF certification, and the research behind minimally processed pet food. We dig into microbiome findings, metabolomics (what it is and why it matters), process-induced toxins (like AGEs), transitioning from kibble, costs, toppers, and the truth about “picky eaters.” We also cover feline feeding quirks, dental health myths, and practical safety tips for pet parents.In This Episode- What “raw” really means today—homemade vs. commercial, and why that distinction matters- How Instinct approaches safety: vetted suppliers, HPP, test-and-hold, and SQF certification- Science check: microbiome, metabolomics, and why minimally processed can shift health markers- Process-induced toxins (AGES, acrylamides) and where heat processing fits in- Balanced diets 101: why “raw liver only” (or chicken-and-pasta!) isn't complete- Transitioning safely: step-wise switchovers, probiotics, and topper strategies for big-dog budgets- Cats! Palate development, why free-choice dry backfires, and hydration from raw/canned- Dental health: kibble vs. functional dental diets, bones, and risks to avoid- Picky vs. overweight: how feeding habits (and treats) drive confusionKey Takeaways- Commercial raw ≠ homemade raw; safety and balance depend on process and formulation.- Properly made raw diets can be complete, balanced, and tested—and show promising health signals.- Even 25% raw as a topper may confer benefits; meet owners where they are.- Treats should stay under 10% of daily calories; measure meals, don't free-feed cats.- Transition slowly (25% steps) and consider probiotics for sensitive pets.https://instinctpetfood.com/Dr. Susan Wynn, DVM, DACVIM (Nutrition) — Senior Director of Scientific Affairs, Nature's Variety/Instinct; long-time clinician and researcher in integrative nutrition.JC Cash, CVT — Educator and industry liaison focused on raw diet safety and veterinary outreach.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

What exactly is a “raw diet,” and how do you make it safely? Host Dr. Alice Jeromin welcomes Dr. Susan Wynn, DVM, DACVIM (Nutrition)—Senior Director of Scientific Affairs at Nature's Variety/Instinct and former president of the American Holistic Veterinary Medical Association—along with JC Cash, CVT. They break down homemade vs. commercial raw diets, high-pressure pasteurization (HPP), supplier quality, SQF certification, and the research behind minimally processed pet food. We dig into microbiome findings, metabolomics (what it is and why it matters), process-induced toxins (like AGEs), transitioning from kibble, costs, toppers, and the truth about “picky eaters.” We also cover feline feeding quirks, dental health myths, and practical safety tips for pet parents.In This Episode- What “raw” really means today—homemade vs. commercial, and why that distinction matters- How Instinct approaches safety: vetted suppliers, HPP, test-and-hold, and SQF certification- Science check: microbiome, metabolomics, and why minimally processed can shift health markers- Process-induced toxins (AGES, acrylamides) and where heat processing fits in- Balanced diets 101: why “raw liver only” (or chicken-and-pasta!) isn't complete- Transitioning safely: step-wise switchovers, probiotics, and topper strategies for big-dog budgets- Cats! Palate development, why free-choice dry backfires, and hydration from raw/canned- Dental health: kibble vs. functional dental diets, bones, and risks to avoid- Picky vs. overweight: how feeding habits (and treats) drive confusionKey Takeaways- Commercial raw ≠ homemade raw; safety and balance depend on process and formulation.- Properly made raw diets can be complete, balanced, and tested—and show promising health signals.- Even 25% raw as a topper may confer benefits; meet owners where they are.- Treats should stay under 10% of daily calories; measure meals, don't free-feed cats.- Transition slowly (25% steps) and consider probiotics for sensitive pets.https://instinctpetfood.com/Dr. Susan Wynn, DVM, DACVIM (Nutrition) — Senior Director of Scientific Affairs, Nature's Variety/Instinct; long-time clinician and researcher in integrative nutrition.JC Cash, CVT — Educator and industry liaison focused on raw diet safety and veterinary outreach.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

Host Dr. Joel Berg is joined by Dr. Tim Wright on this episode of little teeth, BIG Smiles for a discussion of hot topics in dentistry and how those topics make it into the profession's academic publications. Dr. Wright also delves into his experience as Editor of JADA, the Journal of the American Dental Association. Now in his fourth year, he explains the manuscript submission and review process, as well as the topics he anticipates being the next big “cover stories” and emerging topics. Guest Bio: Tim Wright received his DDS degree from West Virginia University and completed his Pediatric Dentistry training and Master of Science Degree at the University of Alabama at Birmingham. He currently is a Professor in the Division of Pediatric Dentistry and Public Health at The Adams School of Dentistry at the University of North Carolina, Chapel Hill, where he has served as Pediatric Dentistry Department Chair and Department of Endodontics Interim Chair. He is a Diplomate of the American Board of Pediatric Dentistry, a Fellow of the American Academy for the Advancement of Science, and a Past President of the American Association of Dental Research. He has Chaired the Counsel of Scientific Affairs for the American Dental Association and American Academy of Pediatric Dentistry. He has published over 200 peer reviewed scientific manuscripts, edited three textbooks and authored 27 text chapters. Dr. Wright is the Editor in Chief of the Journal of the American Dental Association and Chair of the AAPD Evidence Based Dentistry Committee.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Linda Chu speaks with Dr. Andrew Trout, Professor of Radiology and Director of Clinical Research at Cincinnati Children's, and Dr. Erin Angel, Vice President of Research and Scientific Affairs at GE HealthCare. They discuss the unique challenges of pediatric imaging and how collaboration and technology are advancing care for young patients while improving imaging for all. Sponsored by GE HealthCare.

Today on MeatsPad, Dr. Mandy Carr Johnson, Sr. Executive Director of Scientific Affairs at NCBA, discusses the Beef Quality Audit, producer education, proper injection practices, and marbling's impact on meat quality. She also highlights consumer expectations and the need to engage students in the beef industry.

An episode from The Holistic Navigator. This is not to diagnosis or treat any disease/illness. Consult your physician before taking supplements or medications OR before you stop taking medications. This is for entertainment/informational purposes only! How's your stress level these days? Chances are if you're anything like us, tensions are running high with quarantine orders still in place throughout most of the country. And while hope for a return to normalcy is in sight, people across the nation have lost jobs, are stuck inside with family, and are trying their best to navigate these uncertain times. With these new sources of stress in our lives, our bodies may have a difficult time coping. Meet Cheryl: On this week's episode we have the opportunity to speak with somebody who can help us navigate these increasingly stressful situations. Cheryl Myers is the Chief of Scientific Affairs & Education for Europharma and a wealth of knowledge when it comes to the adrenal glands and adrenal fatigue. She walks us through the function of our adrenal glands, what contributes to adrenal fatigue and many of the common symptoms associated with tired adrenal glands. She and Ed then talk about several options to help return your adrenals to appropriate function, including several wonderful options from our friends at Terry Naturally. Some Topics We Discuss: What do the adrenal glands do? (3:40) What are the symptoms of people that have adrenal fatigue? (9:52) Should we test our cortisol levels and what should we look for? (13:17) How do we nourish the adrenal glands? (16:48) Is there anyone who should not use Adrenaplex? (23:52) Sleep is an essential part of adrenal function. How do we address that issue? (26:19) This podcast is powered by ZenCast.fm

Dr. Joel Berg is joined by cariology expert Dr. Brian Novy for a discussion on all there's still to learn about dental caries. Dr. Novy delves into the importance for practitioners to understand the science of cariology, particularly when working with patients and families that may be opposed to traditional treatments, like fluoride. He also shares his personal path in evidence-based dentistry research and how this work has improved his approach to educating the future generation of dentists. Guest Bio: Often described as “The tenth dentist,” Dr. Brian B. Nový has faculty appointments at Virginia Commonwealth University and Harvard School of Dental Medicine. He served on the American Dental Association Council of Scientific Affairs from 2010-2014, and in 2016 was appointed the consumer representative to the United States Food & Drug Administration Dental Products Panel. His papers are published in various journals including the Journal of the American Dental Association, the Journal of Dental Research, the Journal of Evidence Based Dentistry, Dentistry Today, Inside Dentistry, Dental Economics, Compendium, the National Academies of Medicine, and the International Journal of Equity in HealthSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Flow Stars, we're joined by Anis Larbi, Medical & Scientific Affairs, Beckman Coulter Life Sciences. Anis chats about his experience working at the prestigious A*STAR in Singapore, where he led a dual career as both a principal investigator and the head of a core flow cytometry facility.He also shares his advocacy of networking, explains this inspired him to make the leap from academia to industry and discusses some of the snobbery some academics have about this transition.Watch or listen to all episodes of Flow Stars: flowstars.bitesizebio.com

Dr. Lisa Mathew interviews Gary Trendel, vice president of Endoscopy Solutions Ecosystem and Dr. Ruhy Patel, Medical and Scientific Affairs lead for the Endoscopy Solutions Ecosystem and Digital Units at Olympus. Odin Medical, an Olympus company, recently received 510K clearance from the U.S. Food and Drug Administration for the first cloud-based Artificial Intelligence technology designed to assist gastroenterologists in detecting colorectal polyps during colonoscopy procedures. The CADDIE, or computer-aided detection (CADe) device, works by analyzing colonoscopy video in real-time and using visual markers to alert the endoscopist to the potential presence of polyps. A prospective, multi-center randomized controlled trial successfully demonstrated the efficacy and safety of the CADDIE device, underscoring its potential to enhance detection capabilities and patient care without increasing procedural risks or duration. Join Dr. Mathew, Mr. Trendel, and Dr. Patel as they discuss the potential for AI in improving patient care, and what independent GI physicians should understand about AI platforms that assist in detecting polyps during colonoscopy. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 75, presented by TissueCypher from Castle Biosciences

In this episode of the PricePlow Podcast, Mike and Ben welcome back Katie Emerson of Kyowa Hakko USA after Katie's year and a half hiatus from the PricePlow Podcast. They're joined by first-time guest Tony Miano, Director of sales and business development and the man behind putting Cognizin® citicoline into so many numerous beverage innovations. Recording from Expo West 2025 at the Kyowa Hakko booth, the team dives into exciting research developments for both Cognizin and Setria® Glutathione, with particular focus on Setria for sport applications. Katie Emerson is Back, and Doing Serious Research at Kyowa Hakko Katie, now Senior Manager of Scientific Affairs at Kyowa Hakko, shares her enthusiasm for leading multiple new research initiatives, including three upcoming Cognizin studies and renewed research on Setria Glutathione. The conversation explores how Kyowa bridges academic rigor with practical industry applications, uncovering quality structure-function claims based on existing research while developing new studies to expand their ingredients' potential applications in sports nutrition and cognitive health. Subscribe to the PricePlow Podcast for more conversations with industry thought leaders on the science behind effective supplementation! https://blog.priceplow.com/podcast/kyowa-hakko-2025-research-updates Video: Mike and Ben Interview Tony and Katie at Expo West 2025 https://www.youtube.com/watch?v=N5QmZWwotqc Detailed Show Notes: New Research Underway at Kyowa Hakko It's good to be back! (0:00) – Introductions: Reconnecting with Katie Emerson at Expo West 2025 (3:00) – Katie as the Bridge Between Academia and Industry (4:15) – Expanded Structure-Function Claims for Cognizin (7:15) – Deep Dive on Aldehydes and Oxidative Stress (8:30) – From “Supports” to “Improves”: Strengthening Claims (10:15) – New Research Areas: Mood, Motor Function, and Sports Performance (11:30) – Setria Glutathione and Cognizin Connection (12:30) – Kyowa Hakko's Approach to Ingredient Synergy (14:00) – Review of Setria Research Studies (16:30) – Extracting Value from Imperfect Studies (18:30) – Setria for Sport: Rebranding and Positioning (20:30) – Labeling and Positioning Setria for Sport (22:15) – Solution-Based Approach to Customer Needs (23:15) – Flow-Mediated Dilation and Claims Development (24:45) – Navigating Regulatory Language for Pump Claims (26:00) – Oral Glutathione Bioavailability (29:15) – Closing Remarks and Acknowledgments Where to Follow and Learn More Kyowa Hakko USA: PricePlow.com/kyowa-hakko and kyowa-usa.com Katie Emerson: LinkedIn Tony Miano: LinkedIn Cognizin Citicoline: blog.priceplow.com/supplement-ingredients/cognizin Setria Glutathione: See GHOST Vitamin C + Setria Glutathione... Read more on the PricePlow Blog

Dr. Lauren Yap joins host Dr. Joel Berg to chat about the upcoming AAPD Pediatric Oral Health Advocacy Conference (POHAC) in Washington, DC. Each year, hundreds of early career pediatric dentists visit the nation's capital to advocate for the issues impacting the profession and optimal oral health of all children with congressional staff. Dr. Yap shares her experiences as a previous POHAC attendee, as well as how she encourages her peers to seize any opportunity to be a strong voice for themselves and their patients, whether it be in the operatory to the state or national level. Guest Bio: Lauren C. Yap, DMD, MPH, is a Clinical Associate Professor in the Division of Pediatric Dentistry and serves as the Assistant Program Director for the Postdoctoral Pediatric Dental Residency Program at the University of Pennsylvania School of Dental Medicine and Children's Hospital of Philadelphia. She earned her dual degree in Dentistry (DMD) and Public Health (MPH) from the Temple University Kornberg School of Dentistry and College of Public Health in 2019 and subsequently completed an Advanced Education in General Dentistry Certificate in Hawaii, followed by a Pediatric Dentistry Certificate at Geisinger Medical Center in Danville, PA. Board-certified by the American Board of Pediatric Dentistry, Dr. Yap is an active leader in the field, currently serving as the Pennsylvania Public Policy Advocate for the American Academy of Pediatric Dentistry (AAPD) and as a member of the Committee on Scientific Affairs. She is also a recent graduate of the ADA Institute for Diversity in Leadership (2024) and proudly serves as the Third District Representative for the American Dental Political Action Committee (ADPAC). Before pursuing her dental education, Dr. Yap worked as an elementary school math teacher and served as a research assistant at the National Institutes of Health (NIH) within the Center for Asian Health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

If you have a picky eater at home, you're not alone! I'm right in the trenches with you. I've noticed that many parents find mealtime to be one of the most frustrating parts of the day, wondering how to get their child to try new foods without a battle. That's why I had to chat with Amanda Blechman, a registered dietitian, recipe developer, and mom of two, to help us parents navigate the tricky world of picky eating. I loved this episode with Amanda — she shared expert insights on what parents might be unintentionally not helping the situation, practical strategies to expand our child's palate without pressure or power struggles, and so much more. Whether you're dealing with a toddler who refuses vegetables or a child stuck in a chicken-nuggets-only phase, this episode is packed with helpful tips to make mealtimes smoother and more enjoyable for the whole family. Who is Amanda Blechman? Amanda Blechman is a registered dietitian, recipe developer, and mom of two young children who loves to combine her passions of food and family in her work. As part of the Nutrition and Scientific Affairs team at Danone North America, Amanda provides scientific guidance to support nutrition communications, outreach, and education for healthcare professionals and consumers. Amanda is also a creative cook and recipe developer, and in her free time, she enjoys sharing helpful tips on social media to make family meals less daunting for parents and caregivers. What Did We Discuss? As I mentioned, I got to chat with Amanda about picky eaters and how we can help them become adventurous eaters. Here are several of the questions that we covered in our conversation: When you hear someone say they have a picky eater, what's the first thing that goes through your mind? Why do you believe some kids are picky eaters and others are more adventurous eaters? What tips do you have for parents with kids who are picky eaters? Are there things that parents might be doing wrong that are not helping their kids with their eating? What are things parents shouldn't do? How do you feel about “letting them starve”? Some parents refuse to make another, different meal for their picky child and say, “If you're not going to eat what the family is eating, you're not going to eat at all.” What are your thoughts on this? If you disagree with it, what should parents do instead? What are some easy ways for parents to introduce and encourage new food into their child's diet? If parents could do one thing today to really help their child become a more adventurous eater, what would it be? Can you share some easy tips on creating a well-rounded lunchbox for a picky eater? What do parents not know about pediatric nutrition but need to know? Where do you see the future of pediatric nutrition heading, and what impact do you hope to have on the industry? I know all too well — and Amanda confirmed! — that conquering picky eating doesn't happen overnight. However, with patience, consistency, and these different approaches, parents can help their children build a more positive relationship with food. Amanda's expert advice reminds us that mealtimes should be about exploration, not coercion, and that small wins — like a child simply touching a new food — are steps in the right direction. Amanda's Resources Website: danonenorthamerica.com Instagram: @amandablechman LinkedIn: Amanda (Soled) Blechman, RD, CDN Mentioned in the Episode Bento box with five compartments Happy Tot bars Thank you for listening to our podcast! If you found this episode helpful, be sure to share it with another parent who could use some encouragement. And as always, be sure to subscribe to Chick Chat: The Baby Chick Podcast for more empowering conversations like this one, leave us a review, and follow us on our podcast Instagram page @thebabychickchat for more inspiring content. Cheers to raising adventurous eaters! Learn more about your ad choices. Visit megaphone.fm/adchoices

Elevated GP - www.theelevatedgp.com Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

Abdallah El Ali, a Human-Computer Interaction (HCI) researcher with a background in cognitive science discusses trustworthy AI, explainability and transparency with Ahmad Tafti from the University of Pittsburgh and Humanitarian AI Today's Producer, Brent Phillips. Dr. Abdallah El Ali, a Research Scientist at the Research Institute for Mathematics and Computer Science in the Netherlands (Centrum Wiskunde & Informatica) who is also an Assistant Professor at Utrecht University and Dr. Ahmad Tafti, Director of the Pitt HexAI Research Laboratory at the University of Pittsburgh and Interim Director of Scientific Affairs with Pitt's Computational Pathology and AI Center of Excellence (CPACE) and head of AI at Youki GmbH provide insight to individuals interested in humanitarian applications of artificial intelligence on human-computer interaction, information transparency and challenges associated with human cognition, attention, learning and information overload. The discussion touches on emerging transparency regulations governing uses of AI systems, the impact of AI generated content on our lives and how humans process transparency information on uses of AI and data, AI generated content and on the functioning of AI algorithms. The discussion is especially valuable for humanitarian actors considering information disclosure strategies on uses and risks associated with AI. The episode builds on discussions on AI transparency launched by the UK Humanitarian Innovation Hub (UKHIH) and Elrha, and combines insight gained from research into health AI applications and explainability.

Mia L. Geisinger, DDS, MS is a Professor, Director of Advanced Education in Periodontology, and Acting Chair of the Department of Periodontology in the University of Alabama at Birmingham (UAB). Dr. Geisinger received her BS in Biology from Duke University, her DDS from Columbia University School of Dental Medicine, and her MS and Certificate in Periodontology and Implantology from the University of Texas Health Science Center at San Antonio. Dr. Geisinger is a Diplomate in the American Board of Periodontology and a Fellow in the International Team for Implantology, the International College of Dentists and the American College of Dentists. She has served as the President of the American Academy of Periodontology Foundation, as the Chair of the American Dental Association's Council on Scientific Affairs, as a member of the Board of Directors of the American Dental Association Science and Research Institute, and on multiple national and regional organized dentistry committees. She currently serves as the President-Elect and on numerous AAP and ADA committees and task forces. She has authored over 75 peer-reviewed publications and serves on the editorial board of several publications. Her research interests include periodontal and systemic disease interaction, implant dentistry in the periodontally compromised dentition, and novel treatment strategies for oral soft and hard tissue regeneration. She lectures nationally and internationally on topics in periodontology and oral healthcare.

Dr. Harlyn Susarla joins Newly Erupted and host Dr. Joel Berg to discuss the importance of embracing leadership opportunities, along with strategics risks, for early career pediatric dentists to effect positive change. She shares her firsthand experiences with exiting her comfort zone and how those situations built up her confidence in her own expertise and ability to ask the right questions – including one that saved a child's life. Guest Bio: A board-certified pediatric dentist, Dr. Harlyn K. Susarla is committed to preserving, protecting, and promoting high quality, equitable healthcare for every child. Dr. Susarla is currently part of a multi-disciplinary team at Seattle Children's Hospital, where her clinical practice focuses primarily on children with complex medical conditions, developmental or behavioral differences, as well as those requiring emergency care. Dr. Susarla is also an Affiliate Assistant Professor of Pediatric Dentistry at the University of Washington School of Dentistry. She previously worked in a private practice environment, and at the Seattle Children's Odessa Brown Children's Clinic, which provides medical, dental, behavioral health and nutrition services to children, regardless of a family's ability to pay. Dr. Susarla completed her undergraduate education at Wellesley College. She then completed a Master of Public Health degree at Boston University, dental degree at the Harvard School of Dental Medicine, and pediatric dental residency at the University of Maryland School of Dentistry. She is a Fellow of the American Academy of Pediatric Dentistry (AAPD), the Pierre Fauchard Academy, and the American College of Dentists. Dr. Susarla has had the privilege of being an advocate for pediatric dentistry and public health at the local, regional, and national levels. She is Immediate Past President of the Seattle-King County Dental Society and serves on the Washington State Dental Association's Diversity, Equity, and Inclusion Workgroup and Nominations Committee. A past president of the Washington State Academy of Pediatric Dentistry, Dr. Susarla is President-Elect of the Western Society of Pediatric Dentistry, a Trustee of the American Academy of Pediatric Dentistry Foundation, Vice President of the College of Diplomates of the American Board of Pediatric Dentistry, Chair of the AAPD Committee on Early Career Pediatric Dentists, the Western Representative for the AAPD Council on Scientific Affairs, and a consultant on the AAPD Consumer Review Committee. Dr. Susarla is also involved in her local community. She is a member of the Junior League of Seattle and serves on the board of her children's school.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

*This video is part of our educational video series on clinical trials. Clips will cover three key areas: clinical trial strategy, clinical trial execution, and regulatory expertise in clinical trials. Please ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠reach out to RQM+⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ if you need support with clinical trials.* In the final installment of this three-part series, Jaishankar Kutty, Ph.D. concludes the discussion with former FDA lead reviewer Ryan Randall and ex-BSI clinical compliance head Amie Smirthwaite (current RQM+ Senior VP of Scientific Affairs) on the intricacies of successful regulatory submissions in clinical trials. Key topics covered: Critical study design elements that can make or break a regulatory submission Navigating global clinical studies and patient population requirements The importance of ISO 14155 compliance in EU submissions Special considerations for niche and orphan devices US Humanitarian Device Exemption (HDE) pathway insights Future developments in EU pathways for rare disease technologies Strategies for managing studies with limited patient populations These experts provide crucial insights into avoiding common pitfalls in study design and execution, while offering unique perspectives on specialized regulatory pathways for rare diseases and underserved populations. Learn how to navigate these complex regulatory landscapes and optimize your submission strategy for success in both US and EU markets. --

As virus season kicks into high-gear--between colds, the flu, and Covid-19--there's another virus affecting our most-vulnerable populations that you may not think about--and that is RSV (respiratory syncytial virus). In fact, this particular virus sidelined renowned actress and executive producer, Jennifer Beals. After her experience with RSV, she became a spokesperson for GSK this October -- which is RSV Awareness Month. Beals -- known for her iconic role in the film "Flashdance" and the T.V. series, "The L Word" -- shares her story with Nicole. Also joining this conversation is Dr. Leonard Friedland, the Vice President and Director of Scientific Affairs and Public Health for GSK in North America. He details what preventative measures are available, and what we need to be on the look out for to keep our families and loved ones safe. It's a quick listen packed with a lot of great health information! -----------------------------------SHOW NOTES:Host: Nicole Nalepa | @NicoleNalepaTVGuests: Jennifer Beals & Dr. Leonard FriedlandInstagram: @thejenniferbealsWebsite: www.sidelineRSV.com 

*This video is part of our educational video series on clinical trials. Clips will cover three key areas: clinical trial strategy, clinical trial execution, and regulatory expertise in clinical trials. Please ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠reach out to RQM+⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ if you need support with clinical trials.* In part two of a three-part series, Jaishankar Kutty, Ph.D. continues the discussion with former FDA lead reviewer Ryan Randall and ex-BSI clinical compliance head Amie Smirthwaite (current RQM+ Senior VP of Scientific Affairs) on the intricacies of successful regulatory submissions in clinical trials. Key topics covered: Challenges in demonstrating safety and performance/efficacy for medical devices Differences between FDA and EU approaches to clinical evidence The impact of evolving device designs on clinical studies Importance of pre-submission meetings with regulatory bodies Complexities of the EU reimbursement landscape Strategies for dealing with small sample sizes in clinical data The shift in the EU regulatory landscape and its impact on manufacturers Whether you're a seasoned professional or new to the field, this discussion offers crucial perspectives on optimizing your regulatory submission strategy for medical devices and IVDs in both the US and EU markets. Don't miss this opportunity to learn from top industry experts and enhance your understanding of the regulatory review process in clinical trials! --

*This video is part of our educational video series on clinical trials. Clips will cover three key areas: clinical trial strategy, clinical trial execution, and regulatory expertise in clinical trials. Please ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠reach out to RQM+⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ if you need support with clinical trials.* In part one of a three part series, Jaishankar Kutty, Ph.D. hosts former FDA lead reviewer Ryan Randall and ex-BSI clinical compliance head Amie Smirthwaite (current RQM+ Senior VP of Scientific Affairs) to unpack the intricacies of successful regulatory submissions in clinical trials. Key topics covered: Essential stakeholders in the clinical trial approval process for both US and EU markets The importance of early engagement with regulatory bodies and payers Reviewer approaches to clinical data sets and benefit-risk analyses Strategies for navigating failed primary endpoints The balance between statistical and clinical significance in regulatory decision-making Differences in approach between MDD and MDR in the EU The impact of study design and protocol adherence on regulatory review These experts provide invaluable insights into the mindset of regulatory reviewers, offering guidance on how to present clinical data effectively and navigate complex regulatory landscapes. Whether you're a seasoned professional or new to the field, this discussion offers crucial perspectives on optimizing your regulatory submission strategy for medical devices and IVDs in both the US and EU markets. Don't miss this opportunity to learn from top industry experts and enhance your understanding of the regulatory review process in clinical trials! --

This past week, Foreign Policy magazine hosted a live taping on Marine Protected Areas at the United Nations General Assembly. This discussion was moderated by Matt Rand, Senior Director of Marine Habitat Protection at the Pew Charitable Trusts.   Joining Matt on the stage was: Monica Medina, the former Assistant Secretary of State for Oceans and International Environmental and Scientific Affairs. She's currently a distinguished fellow at Conservation International. Joel Johnson is the President and CEO of the National Marine Sanctuary Foundation. Editrudith Lukanga  is the Founder of EMEDO, an organization that supports small-scale fisheries in Tanzania and she currently leads the Secretariat of the African Women Fish-workers Network. And Jim Leape is the Co-Director and William and Eva Price Senior Fellow at the Stanford Woods Institute for the Environment at Stanford University.  Learn more about your ad choices. Visit megaphone.fm/adchoices

This presentation and panel was recorded 12 September 2024. We encourage you to download the slides presented during this session by ⁠⁠⁠⁠⁠⁠completing the form on this page⁠⁠⁠⁠⁠⁠. Please join us live for future shows for the chance to participate in the chat and ask your own questions! We generally hold one RQM+ Live! panel discussion per month (in addition to occasional traditional webinars) and you can sign up for these events and more at the ⁠⁠⁠⁠⁠⁠⁠Knowledge Center⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠at RQMplus.com. Thank you for tuning in.

  John Burgess Obituary Join Journal Club Download my free guide to Internal Bleaching PDF Follow @dental_digest_podcast Instagram Connect on Instagram: @dr.melissa_seibert on Instagram DOT - Use the Code DENTALDIGEST for 10% off Dr. John O. Burgess is a graduate of Emory University School of Dentistry. He received his M.S. in Biomedical Sciences from the University of Texas Health Science Center in Houston, Texas, completed a one year General Practice Residency and a two year General Dentistry Residency.    Currently Dr. Burgess is the assistant Dean for Clinical Research at the University of Alabama at Birmingham as well as Director of the Graduate Biomaterials Program. He has served as a military consultant in general dentistry to the Air Force Surgeon General. He received certification from the American Board of Dentistry and is a diplomat of the Federal Services Board of General Dentistry. He is a member of the American Academy of Esthetic Dentistry, The Academy of Restorative Dentistry, the American Dental Association, the American and International Association for Dental Research, and the Academy of Operative Dentistry. Dr. Burgess is a fellow of the Academy of Dental Materials and the American College of Dentists. A prolific researcher, Dr. Burgess has authored more than 400 articles, abstracts and textbook chapters and currently receives research funding from federal and industry sources. He is a reviewer for four dental journals and is a member of the advisory board for the Dental Advisor and the Editorial Board for Inside Dentistry. He is a past chair of the Biomaterials Section of the American Association for Dental Schools and has served on the Executive Board for the American Association for Dental Research. Currently he is a member of the American Dental Association’s Council on Scientific Affairs and a member of two ADA committees for specification development for materials and devices. He is active in clinical evaluations of dental materials and is an investigator on clinical protocols evaluating adhesives, ceramic restoratives, fluoride releasing materials, low shrinkage posterior composites and impression materials. Dr. Burgess lectures extensively nationally and internationally and has presented more than 900 continuing education courses.   Dr. Burgess is married to a wonderful lady, Patricia. They now reside in Birmingham, AL.

  John Burgess Obituary Join Journal Club Download my free guide to Internal Bleaching PDF Follow @dental_digest_podcast Instagram Connect on Instagram: @dr.melissa_seibert on Instagram DOT - Use the Code DENTALDIGEST for 10% off Dr. John O. Burgess is a graduate of Emory University School of Dentistry. He received his M.S. in Biomedical Sciences from the University of Texas Health Science Center in Houston, Texas, completed a one year General Practice Residency and a two year General Dentistry Residency.    Currently Dr. Burgess is the assistant Dean for Clinical Research at the University of Alabama at Birmingham as well as Director of the Graduate Biomaterials Program. He has served as a military consultant in general dentistry to the Air Force Surgeon General. He received certification from the American Board of Dentistry and is a diplomat of the Federal Services Board of General Dentistry. He is a member of the American Academy of Esthetic Dentistry, The Academy of Restorative Dentistry, the American Dental Association, the American and International Association for Dental Research, and the Academy of Operative Dentistry. Dr. Burgess is a fellow of the Academy of Dental Materials and the American College of Dentists. A prolific researcher, Dr. Burgess has authored more than 400 articles, abstracts and textbook chapters and currently receives research funding from federal and industry sources. He is a reviewer for four dental journals and is a member of the advisory board for the Dental Advisor and the Editorial Board for Inside Dentistry. He is a past chair of the Biomaterials Section of the American Association for Dental Schools and has served on the Executive Board for the American Association for Dental Research. Currently he is a member of the American Dental Association’s Council on Scientific Affairs and a member of two ADA committees for specification development for materials and devices. He is active in clinical evaluations of dental materials and is an investigator on clinical protocols evaluating adhesives, ceramic restoratives, fluoride releasing materials, low shrinkage posterior composites and impression materials. Dr. Burgess lectures extensively nationally and internationally and has presented more than 900 continuing education courses.   Dr. Burgess is married to a wonderful lady, Patricia. They now reside in Birmingham, AL.

Health and wellness are top priorities for many American consumers. With high nutrient density and key benefits for gut health and bone density, yogurt and cultured dairy products are increasingly popular foods to meet consumer preferences. What does the latest science reveal about the health benefits of these products? How can companies balance nutritional goals with consumer taste preferences? What innovations are on the horizon for this category?Tune in to this week's episode of The Dairy Download to explore how leading dairy companies are leveraging the health benefits of yogurt and cultured dairy products, along with the latest consumer trends! We are excited to be joined by two experts leading the charge in the production and consumer education around these nutritious products.Jesse Merrill, founder & CEO of Good Culture, and Amanda Blechman, Director of Nutrition and Scientific Affairs at Danone North America, discuss the growth of cultured dairy and why it's an excellent choice for consumers looking to support their nutritional needs. Don't miss this insightful conversation about the dynamic world of yogurt and cultured dairy!If your company is interested in sponsoring a block of episodes of The Dairy Download, contact IDFA's Michael Goodin at mgoodin@idfa.org.Like the show?Rate The Dairy Download on Apple Podcasts!

In this episode, Dr. Jill O'Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute (CRI), discusses the fascinating history of cancer immunotherapy, recent breakthroughs, and the potential role of focused ultrasound in enhancing immunotherapy treatments. The conversation explores current challenges and opportunities in cancer immunotherapy, including the need for personalized treatment approaches and the promising potential of combining immunotherapy with other modalities like focused ultrasound. Dr. O'Donnell-Tormey explains key concepts such as checkpoint inhibitors and CAR T-cell therapy, making complex ideas accessible to listeners. Listeners will gain valuable insights into the collaborative efforts between CRI and the Focused Ultrasound Foundation, learning how this partnership is driving innovation in cancer treatment. Dr. O'Donnell-Tormey also reflects on her career achievements and the evolving landscape of cancer research. This episode offers a unique opportunity to learn from a leading expert in the field, providing a deeper understanding of the latest advancements in cancer immunotherapy and the potential for innovative technologies like focused ultrasound to improve treatment outcomes for cancer patients. For more information about CRI visit cancerresearch.org SHOW TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/